Literature DB >> 7538540

Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1.

V Udhayakumar1, D Anyona, S Kariuki, Y P Shi, P B Bloland, O H Branch, W Weiss, B L Nahlen, D C Kaslow, A A Lal.   

Abstract

The 42-kDa, C-terminal region of the merozoite surface protein-1 (MSP-1) of Plasmodium falciparum is a putative malaria vaccine candidate Ag. Nine synthetic peptides corresponding to predicted T cell sites of MSP-1 in blocks 15 and 16 and eight overlapping peptides representing the conserved block 17 were used to identify naturally immunogenic epitopes. These peptides were tested for their ability to induce proliferation of PBMC from residents in western Kenya, where malaria transmission is holoendemic. Six peptides (PL145, PL146, PL147, PL148, PL149, and PL150) from blocks 15 and 16 induced a positive proliferative response in > 30% of the individuals tested, and three peptides (PL151, PL152, and PL153) induced a proliferative response in < 25% of the donors. Among these peptides, PL146 was from the highly conserved region, PL150 was from a polymorphic region, and all other peptides were from a dimorphic region of blocks 15 and 16. In block 17, only three peptides, PL99, PL100, and PL103, induced proliferation in 30 to 37% of the volunteers. The rest of the peptides induced a proliferative response in approximately 13 to 25% of the donors. The plasma from these donors widely reacted with different allelic forms of 19-kDa recombinant proteins representing block 17 and recognized at least two linear B epitopes, PL104 and PL97. In summary, this study revealed that a majority of immunodominant T and B epitopes are localized in the conserved or dimorphic regions that are nonpolymorphic in the 42-kDa protein of MSP-1. This study suggests that incorporation of T epitopes from the dimorphic blocks 15 and 16 in a vaccine construct may be useful to ensure Ag-specific memory responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes.

Authors:  Arlene E Dent; Christopher T Yohn; Peter A Zimmerman; John Vulule; James W Kazura; Ann M Moormann
Journal:  Am J Trop Med Hyg       Date:  2007-08       Impact factor: 2.345

4.  Changes in antigen-specific cytokine and chemokine responses to Plasmodium falciparum antigens in a highland area of Kenya after a prolonged absence of malaria exposure.

Authors:  Lyticia A Ochola; Cyrus Ayieko; Lily Kisia; Ng'wena G Magak; Estela Shabani; Collins Ouma; Chandy C John
Journal:  Infect Immun       Date:  2014-06-23       Impact factor: 3.441

5.  Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1.

Authors:  Y P Shi; U Sayed; S H Qari; J M Roberts; V Udhayakumar; A J Oloo; W A Hawley; D C Kaslow; B L Nahlen; A A Lal
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

6.  Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria.

Authors:  I S Soares; G Levitus; J M Souza; H A Del Portillo; M M Rodrigues
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

7.  Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.

Authors:  Y P Shi; S E Hasnain; J B Sacci; B P Holloway; H Fujioka; N Kumar; R Wohlhueter; S L Hoffman; W E Collins; A A Lal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria.

Authors:  A A Lal; M A Hughes; D A Oliveira; C Nelson; P B Bloland; A J Oloo; W E Hawley; A W Hightower; B L Nahlen; V Udhayakumar
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.

Authors:  Christian M F Okafor; Chiaka I Anumudu; Yusuf O Omosun; Chairat Uthaipibull; Idowu Ayede; Henrietta O Awobode; Alex B Odaibo; Jean Langhorne; Anthony A Holder; Roseangela I Nwuba; Marita Troye-Blomberg
Journal:  Malar J       Date:  2009-11-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.